263 related articles for article (PubMed ID: 14746510)
1. Progress in antisense technology.
Crooke ST
Annu Rev Med; 2004; 55():61-95. PubMed ID: 14746510
[TBL] [Abstract][Full Text] [Related]
2. Antisense strategies.
Crooke ST
Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
[TBL] [Abstract][Full Text] [Related]
3. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
4. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
Orum H; Wengel J
Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
[TBL] [Abstract][Full Text] [Related]
5. Application of antisense oligonucleotides for gene functionalization and target validation.
Bennett CF; Cowsert LM
Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of action of antisense drugs.
Crooke ST
Biochim Biophys Acta; 1999 Dec; 1489(1):31-44. PubMed ID: 10806995
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of Antisense Drugs.
Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
[TBL] [Abstract][Full Text] [Related]
11. Progress in antisense therapeutics.
Crooke ST
Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
[TBL] [Abstract][Full Text] [Related]
12. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.
Bennett CF; Swayze EE
Annu Rev Pharmacol Toxicol; 2010; 50():259-93. PubMed ID: 20055705
[TBL] [Abstract][Full Text] [Related]
13. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
14. A hitchhiker's guide to antisense and nonantisense biochemical pathways.
Branch AD
Hepatology; 1996 Dec; 24(6):1517-29. PubMed ID: 8938189
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
16. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry of antisense oligonucleotides--future opportunities.
Cook PD
Anticancer Drug Des; 1991 Dec; 6(6):585-607. PubMed ID: 1772571
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides for cancer therapy-an overview.
Stahel RA; Zangemeister-Wittke U
Lung Cancer; 2003 Aug; 41 Suppl 1():S81-8. PubMed ID: 12867066
[TBL] [Abstract][Full Text] [Related]
19. Use of antisense oligonucleotides in functional genomics and target validation.
Ravichandran LV; Dean NM; Marcusson EG
Oligonucleotides; 2004; 14(1):49-64. PubMed ID: 15104896
[TBL] [Abstract][Full Text] [Related]
20. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
Mahato RI; Cheng K; Guntaka RV
Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
